Dr. Stefanie Johns, Chief Scientific Officer, will present updates on the Hoth Therapeutics Pipeline, including new proof-of-concept data for HT-ALZ, a novel Alzheimer’s Disease Therapeutic NEW YORK, April 1, 2022 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused…